



REDLABS U.S.A., Inc.

5625 Fox Ave, Suite 369
Reno, NV 89506

Ph (775) 351-1890
Fax (775) 972-1300

Client:	Beach Physicians Medical Group, L.C. 17742 Beach Blvd, Suite 218, Huntington Beach	Chart #:	
		Accession #:	0600726
	Ph: (714) 848-1655 Fax: (714) 847-4348	Requesting Physician: Dr. Basil Aish	
Patient Name:		Insurance Patient ID.:	
Address:	126 24th St New Port Beach CA 92653	Gender:	M
		Received:	11/22/2006
		Collected Date/ Time:	11/20/2006 / 9:00
Remarks:	Received Greater than 24 hours	Reported:	12/8/2006

Laboratory Report

Test Code	Test Description	Normal	Abnormal	Normal Range
RNAA	Rnase L Activity Assay		438	Less than 50

The RNase L Activity Assay measures the amount enzymatic response to a viral attack. However, in the absence of detectable 80 kDa form of RNase L has been cleaved by the action of inflammatory and/or apoptotic enzymes. Therefore, increased RNase L enzymatic activity may be 'normal' (as in the case of overt infection, and produced by the activated 80 kDa form of RNase L) or may be 'abnormal' (as in the case where the 80 kDa form has been cleaved into LMW fragments of RNase L). The latter example is what is routinely observed in immune cells from patients with CFS. Increased activity may or may not correspond to an increasing dysfunctional immune system. The RNase L Activity Assay should be measured in conjunction with the RNase L Protein Assay to determine the level of enzymatic activity as a function of RNase L fragmentation. This marker may be used to stage disease and follow therapy. The results of this test should be considered along with all the clinical data before making a diagnosis.

activity. RNase L activity is normally induced by Interferon in the virus, increased RNase L activity may also be present if the inflammatory and/or apoptotic enzymes. Therefore, increased RNase L enzymatic activity may be 'normal' (as in the case of overt infection, and produced by the activated 80 kDa form of RNase L) or may be 'abnormal' (as in the case where the 80 kDa form has been cleaved into LMW fragments of RNase L). The latter example is what is routinely observed in immune cells from patients with CFS. Increased activity may or may not correspond to an increasing dysfunctional immune system. The RNase L Activity Assay should be measured in conjunction with the RNase L Protein Assay to determine the level of enzymatic activity as a function of RNase L fragmentation. This marker may be used to stage disease and follow therapy. The results of this test should be considered along with all the clinical data before making a diagnosis.

RNAP	Rnase L Protein Quantitation		23.3	Less than 2.0
------	------------------------------	--	------	---------------

The Rnase L Protein Assay measures the amount of Low Molecular Weight (LMW) protein relative to High Molecular Weight (HMW). Increased ratios have been noted in a specific subset of patients with Chronic Fatigue Syndrome (CFS). The presence of this marker may distinguish patients with CFS from those suffering from other chronic immune diseases. The results of this test should be considered along with all the clinical data before making a diagnosis.

Molecular Weight (LMW) protein relative to High Molecular Weight (HMW). Increased ratios have been noted in a specific subset of patients with Chronic Fatigue Syndrome (CFS). The presence of this marker may distinguish patients with CFS from those suffering from other chronic immune diseases. The results of this test should be considered along with all the clinical data before making a diagnosis.

This test was developed and its performance characteristics determined by REDLABS U.S.A., Inc. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.

REDLABS U.S.A., Inc. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.

The information provided in this document is of a personal and confidential nature and intended strictly for the above noted recipient. The contents are medical laboratory test results and are protected by law as privileged and protected information. Any use of information obtained from this document without proper consent of the intended recipient is a criminal act, and will be aggressively prosecuted to the maximum extent allowable by law. If you are not the intended recipient and have received this document in error, please destroy the document and notify REDLABS U.S.A., Inc. at (775) 351-1890 immediately.

The information provided in this document is of a personal and confidential nature and intended strictly for the above noted recipient. The contents are medical laboratory test results and are protected by law as privileged and protected information. Any use of information obtained from this document without proper consent of the intended recipient is a criminal act, and will be aggressively prosecuted to the maximum extent allowable by law. If you are not the intended recipient and have received this document in error, please destroy the document and notify REDLABS U.S.A., Inc. at (775) 351-1890 immediately.

Anton P. Sohn M.D. Laboratory Director